Jubilant Pharmova Expands Radiopharma Capacity with CAD 94.5 Million Investment

Jubilant Pharmova is committing CAD 94.5 million to upgrade its Kirkland, Québec facility.
The project aims to double the production of RUBY-FILL and is supported by CAD 23.8 million in Canadian government backing.

Reader Takeaway: Strong global demand for diagnostics drives capacity expansion; timely facility modernization remains the key execution metric.

What just happened

Jubilant Pharmova’s subsidiary, Jubilant Draximage Inc., has launched a major expansion plan for its Kirkland manufacturing site. The company will invest CAD 94.5 million to modernize infrastructure, with CAD 23.8 million provided by the Strategic Response Fund from the Canadian government. This site is currently the only facility in Canada capable of producing these specific radiopharmaceutical categories.

Why this matters

The Radiopharma division is seeing a sustained surge in demand. Management reported that the customer base for RUBY-FILL has doubled over the past three years. By doubling production capacity, the company is positioning itself to secure a reliable supply chain to meet this rising global interest in nuclear medicine diagnostics.

Management Commentary

CEO Harsher Singh described the investment as a validation of the firm’s innovation in nuclear medicine. He noted that the expansion is expected to generate high-value jobs in Quebec and improve the long-term reliability of essential diagnostic treatments for patients globally.

What to track next

Investors should monitor the construction timeline and the pace of facility commissioning. Future earnings reports will likely highlight the impact of this increased capacity on Radiopharma segment margins and revenue growth as the company moves to capture more market share.